Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04390724 · ClinicalTrials.gov registry record
Optimizing Y90 Therapy for Radiation Lobectomy
A clinical trial of Metastatic Cancer and HCC, sponsored by Northwestern University.
- Recruiting
- Registry status
- 104
- Enrollment target
- 1
- Study location
NCT04390724 is a study of Metastatic Cancer and HCC that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 104 participants, below the 443-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04390724, a study of Metastatic Cancer and HCC, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- 104 participants
- Enrollment target
- 1
- Study location
Study Summary
HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection. There will be 2 Patient Groups. The first group of patients will be treated with Y90 dose and embolic load as per standard-of-care. The second group of patients will be treated with the optimal Y90 dose and embolic load found in Patient Group 1.
Conditions Studied
Interventions
- DEVICE Y90 radioembolization
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2020-07-17 |
| Est. Completion | 2026-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04390724
The ClinicalTrials.gov registry entry for NCT04390724 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 443-participant average among 109 other Metastatic Cancer trials with a reported enrollment target (77% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Metastatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which Y90 radioembolization is the first listed.
NCT04390724 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT04390724 about?
NCT04390724 is a clinical study titled "Optimizing Y90 Therapy for Radiation Lobectomy". HCC resection candidates with inadequate future liver remnant will be enrolled in this study. They will be treated with Y90 radioembolization to help grow the liver enough to undergo liver resection. There will be 2 Patient Groups. The first group of patients will be treated with Y90 dose and emboli...
What is the current status of trial NCT04390724?
This trial is currently recruiting. The enrollment target is 104 participants. The study started on 2020-07-17. Estimated completion is 2026-07.
What conditions does trial NCT04390724 study?
This clinical trial studies the following conditions: Metastatic Cancer, HCC, Transplant, Adult Primary Liver Cancer, Resection.
What interventions are being tested in trial NCT04390724?
The interventions under investigation include: Y90 radioembolization (DEVICE).
Who is sponsoring clinical trial NCT04390724?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04390724 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Evaluating Disparities in Precision Oncology
RECRUITING
-
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
RECRUITING · Phase 1
-
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change
RECRUITING · Phase 2
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer
RECRUITING · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.